Skip to main content
. Author manuscript; available in PMC: 2019 May 15.
Published in final edited form as: Cancer Res. 2018 Feb 22;78(10):2732–2746. doi: 10.1158/0008-5472.CAN-17-1990

Figure 6. Identification of NEK9 and MAP2K4 in association with buparlisib resistance.

Figure 6

A, an outlier expression analysis of the global phosphoproteome found 51 kinases to be enriched in the resistant group (WHIM2 and WHIM12), WHIM12 alone, or WHIM2 alone. Shading indicates the number of phosphosite outliers identified in the specified gene. Blue circles annotate outlier kinase events by sensitivity group (Resistant: WHIM12, WHIM2 versus non-resistant: W6, W21, W30, W4) or resistant sample (WHIM12 versus all others or WHIM2 versus all others), identified based on enrichment (≥ 50% samples containing phosphosite outlier, ≤ 5% FDR using Benjamini-Hochberg adjusted p-values). B, upper panel: MIB data of baseline NEK9 levels. Lower panel: MAP2K4 after buparlisib treatment normalized to respective controls (bars are mean and whiskers are standard deviations). No MAP2K4 peptides were detected in WHIM4’s kinase-enriched MIB samples (missing data/undetected).